Jan de Backer – CEO, Fluidda
Fluidda is the world leader in the field of functional respiratory imaging which combines HRCT scans and computational fluid dynamics technology. CEO Jan de Backer outlines the major developments of…
Address: Groeningenlei 132
2550 Kontich
Groeningenlei 132, 2550 Kontich,Belgium
Tel: +32 3 450 87 20
FluidDA acts as a CRO to support the implementation of the FluidDA imaging biomarkers into clinical trials and clinical practice. To offer a high quality service, FluidDA employs experts in all required fields from medical doctors to biomedical scientists and engineers. A complete package is offered to manage a study from design to (scientific) reporting.
FluidDA has experience in pulmonology, respiratory drug delivery, sleep medicine, maxillofacial surgery and cardiovascular. The company collects stores, manages and analyzes data coming from a variety of imaging modalities such as CT, MRI, Cone Beam CT, SPECT and ultrasound. From clinical studies, FluidDA has gained extensive experience in scanning protocols to achieve proper image quality. FluidDA can write or assist in writing protocols for clinical imaging studies according to GCP guidelines as well as analyzing and writing of study results in international peer reviewed journals.
Fluidda is the world leader in the field of functional respiratory imaging which combines HRCT scans and computational fluid dynamics technology. CEO Jan de Backer outlines the major developments of…
Dr De Backer looking into your background, we see that you have a background in aerospace engineering and applied biomedical computational fluid dynamics that is riddled with awards for your…
Business & Decision Life Science was founded back in 2007, although that department existed within the group’s structure long before that. Could you highlight the reasons why a special business…
Mr Hendrickx, considering that you have been with Sanofi for over a decade, what would you describe as the single most important change in Sanofi’s business model? In essence, it…
Mr Delwart, you have been acting CEO of EuroGenTec for an impressive 19 years. During your tenure, what would you say has been the single most important change in the…
Can you illustrate to our readers the company’s main milestones and key achievements since you took the reins four years ago? In the last years we have experienced a period…
Let us begin by getting an overview of APB’s functions & objectives and your role within the association as General Manager? The Belgian Association of Pharmacists is a federation of…
Mr Bravo, in relation to your previous career in big pharma companies, you have recently made a shift into much smaller entities including Cellerix and TiGenix. What motivated you to…
Looking into your background, we see that you have developed your career in the local industry’s top 3 players: Pfizer, AstraZeneca and Novartis until assuming your position as General Manager…
Oystershell was founded in 1979, however in 2002 the company was taken over by you and your team in a MBO. Can you tell our readers more about what motivated…
Can you tell our readers about B&C Groups main mission and also highlight some of its most notable achievements and milestones since its founding in 1999? Earlier in my career,…
Looking at your background, we see that you have been with IMS for over 12 years. What defines your loyalty to the company? What appeals most to you about IMS?…
Can you begin by giving us a brief overview of Amgen in Belgium and tell our readers more about the company’s history here? Compared to other, well-established multinationals Amgen is…
Mr. De Cuyper, can you start with a brief introduction to the federal agency for medicines and health products (famhp) and its role within the Belgium’s complex regulatory environment? We…
See our Cookie Privacy Policy Here
